Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis

(2015) Nicola De Stefano et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Fingolimod effect on brain volume loss independently contributes to its effect on disability

(2015) MP Sormani et al.   Multiple Sclerosis Journal

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis

(2015) E.-W. Radue et al.   NEUROLOGY

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Fingolimod effect on brain volume loss independently contributes to its effect on disability

(2015) MP Sormani et al.   Multiple Sclerosis Journal

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis

(2014) Richard Nixon et al.   ADVANCES IN THERAPY

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

(2014) Douglas L Arnold et al.   BMC Neurology

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

Mechanisms of white matter damage in multiple sclerosis

(2014) Hans Lassmann   GLIA

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Disease Activity Free Status

(2014) Carolyn J. Bevan et al.   JAMA Neurology

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

(2013) Fred D. Lublin et al.   ANNALS OF NEUROLOGY

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

(2013) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Brain atrophy and lesion load predict long term disability in multiple sclerosis

(2013) Veronica Popescu et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study

(2013) Eva Havrdova et al.   Multiple Sclerosis Journal

Editors' welcome and a working definition for a multiple sclerosis cure

(2013) Brenda Banwell et al.   Multiple Sclerosis and Related Disorders

Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis

(2012) Ernst-Wilhelm Radue   ARCHIVES OF NEUROLOGY

Association between pathological and MRI findings in multiple sclerosis

(2012) Massimo Filippi et al.   LANCET NEUROLOGY

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis

(2011) Luca Prosperini et al.   Multiple Sclerosis Journal

MRI predictors of cognitive outcome in early multiple sclerosis

(2011) M. S. A. Deloire et al.   NEUROLOGY

Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis

(2010) Richard A. Rudick et al.   ARCHIVES OF NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN

Gray matter atrophy and disability progression in patients with early relapsing–remitting multiple sclerosis

(2009) Dana Horakova et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Brain atrophy as an outcome measure for multiple sclerosis clinical trials: A "no-brainer"?

(2009) R. A. Rudick et al.   NEUROLOGY